Aim: The current study was designed to assess the psychotomimetic effects of a moderate dose of JWH-018.
Methods: Twenty-four healthy participants (10 males, 14 females) entered a placebo-controlled, double blind, within-subjects trial and inhaled vapour of placebo or 75μg/kg bodyweight JWH-018. To ascertain a minimum level of intoxication, a booster dose of JWH-018 was administered on an as-needed basis. The average dose of JWH-018 administered was 5.52 mg. Subjective high, dissociative states (CADSS), psychedelic symptoms (Bowdle), mood (POMS) and cannabis reinforcement (SCRQ) were assessed within a 4.5-h time window after drug administration.
JWH-018 caused psychedelic effects, such as altered internal and external perception, and dissociative effects, such as amnesia, derealisation and depersonalisation and induced feelings of confusion.
Conclusion: Overall, these findings suggest that a moderate dose of JWH-018 induces pronounced psychotomimetic symptoms in healthy participants with no history of mental illness, which confirms that SCs pose a serious risk for public health.
- CB1 receptor agonists
- Clinical characteristics
- Clinical study
- HIGH-POTENCY CANNABIS
- ANTIPSYCHOTIC PROPERTIES
Psychotomimetic symptoms after a moderate dose of a synthetic cannabinoid (JWH-018): implications for psychosis
Theunissen, E. (Contributor), Reckweg, J. (Contributor), Hutten, N. (Contributor), Kuypers, K. (Contributor), Toennes, S. W. (Contributor), Neukamm, M. A. (Contributor), Halter, S. (Contributor) & Ramaekers, J. (Contributor), DataverseNL, 4 Oct 2021